Association of OPRK1 rs963549 and rs997917 polymorphisms with opioid use disorder and related phenotypes.

Autor:	Özkan-Kotiloğlu S; Kırşehir Ahi Evran University, Faculty of Science & Art, Department of Molecular Biology & Genetics, Kırşehir, Türkiye., Kaya-Akyüzlü D; Ankara University, Institute of Forensic Sciences, Ankara, 06590, Türkiye., Yalçın-Şahiner Ş; Ankara Training & Research Hospital AMATEM Clinic, Ankara, 06374, Türkiye.; Kütahya Health Sciences University, Faculty of Medicine, Department of Mental Health & Diseases, Kütahya, 43020,Türkiye., Ayaz N; Ankara City Hospital, Ankara, 06800, Türkiye.
Jazyk:	angličtina
Zdroj:	Pharmacogenomics [Pharmacogenomics] 2023 Apr; Vol. 24 (6), pp. 325-334. Date of Electronic Publication: 2023 May 11.
DOI:	10.2217/pgs-2023-0037
Abstrakt:	Aim: To evaluate the association between OPRK1 rs963549 and rs997917 and opioid use disorder (OUD) and related phenotypes. Methods: A sample of 208 individuals with (n = 100) and without (n = 108) OUD were enrolled. OPRK1 rs963549 and rs997917 were analyzed by PCR-RFLP. Craving, opioid withdrawal and the intensity of depressive and anxiety symptoms were measured by the appropriate scales. Results: OPRK1 rs963549 variation showed a trend of association with decreased opioid withdrawal. No significant associations were found between OPRK1 rs963549 and rs997917 polymorphisms and craving, depression or anxiety symptoms. Neither single OPRK1 SNPs nor OPRK1 haplotypes were associated with OUD. Conclusion: Our results could be useful for treatment failures of individuals who experience greater opioid withdrawal due to their OPRK1 rs963549 genotypes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu